CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Pasireotidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02215070
NCT02215070Phase 2Completed
CompareCT.gov

Prevention of Gastrointestinal Toxicity From Total Body Irradiation or High Dose Chemotherapy With Pasireotide

Anthony Sung, MD·interventional·Posted Aug 13, 2014·Updated Nov 17, 2021

In Brief

A Phase 2 clinical trial evaluating Pasireotide for Hematological Malignancies. Completed, enrolled 37 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate if the drug, Pasireotide, is safe and effective in reducing the gastrointestinal side effects of the drugs received to prepare for allogeneic stem cell transplant. The study will also evaluate if Pasireotide is effective in reducing acute and chronic Graft-versus-Host-Disease (GvHD) after transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematological Malignancies
CountriesUnited States
CollaboratorsMassachusetts General Hospital

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 13, 2014
Enrollment StartJan 21, 2015
Primary CompletionFeb 28, 2019
Study CompletionOct 15, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 11.9 years ago

Interventions

Pasireotidedrug

Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.